Evidence map›Paper›PMID 33847207›Full record

ReviewCancer biology & therapy2021

Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review).

Dongdong Xue, Jingzhao Han, Yifan Liu, Hongfang Tuo, Yanhui Peng

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer biology & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. [Alteration of Wnt3a overexpression and its early monitoring value during hepatocellular carcinogenesis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  9. [Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dongdong XueDepartment of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.
Jingzhao HanDepartment of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.
Yifan LiuDepartment of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.
Hongfang TuoDepartment of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.
Yanhui PengDepartment of Hepatobiliary Surgery, General Hospital, Shijiazhuang, Hebei, P. R. China.ORCID 0000-0003-4492-5155
Hebei General Hospital · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of hepatocellular carcinoma (HCC), a malignant tumor, is poor. Tumor recurrence and metastasis are the major challenges for the treatment of HCC. Various studies have demonstrated that exosomes, which are loaded with various biomolecules including nucleic acids, lipids, and proteins are involved in the recurrence and metastasis of HCC. Additionally, exosomes mediate various biological processes, such as immune response, cell apoptosis, angiogenesis, thrombosis, autophagy, and intercellular signal transduction. In cancer, exosomes regulate cancer cell differentiation, development, and drug resistance. Circular RNAs, microRNAs, and proteins in the exosomes can serve as early diagnostic and prognostic markers for HCC. As exosomes are characterized by low immunogenicity and high stability in the tissues and circulation, they can be used to deliver the drugs in cancer therapies.

Indexed as

Carcinoma, HepatocellularExosomesLiver NeoplasmsMicroRNAsGene Expression Regulation, NeoplasticHumansSignal TransductionMicroRNAsdrug resistanceexosomesHepatocellular carcinomamicroenvironmenttargeted treatment

Identifiers

PMID33847207
PMCPMC8183537
OpenAlexW3155986941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.